AstraZeneca PLC
AZN
$77.88
-$0.08-0.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.84% | 18.04% | 13.33% | 16.55% | 7.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.84% | 18.04% | 13.33% | 16.55% | 7.29% |
| Cost of Revenue | 35.14% | 17.52% | 10.56% | 15.38% | 338.53% |
| Gross Profit | 21.48% | 18.15% | 13.91% | 16.79% | -17.68% |
| SG&A Expenses | 36.24% | -3.79% | -1.90% | 8.11% | -5.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 42.86% | 64.29% | 92.35% | 35.00% | 1.41% |
| Total Operating Expenses | 32.53% | 7.46% | 12.03% | 12.37% | 57.53% |
| Operating Income | 1.26% | 69.65% | 18.08% | 30.26% | -41.33% |
| Income Before Tax | 85.73% | 10.65% | 14.80% | 23.78% | 15.30% |
| Income Tax Expenses | 367.74% | 44.16% | 75.00% | 35.37% | 50.00% |
| Earnings from Continuing Operations | 56.41% | 3.99% | 5.93% | 20.84% | 6.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | 0.00% | 50.00% | 0.00% | 200.00% |
| Net Income | 56.25% | 4.00% | 6.00% | 20.85% | 6.55% |
| EBIT | 1.26% | 69.65% | 18.08% | 30.26% | -41.33% |
| EBITDA | -0.90% | 45.69% | 12.76% | 21.02% | -36.55% |
| EPS Basic | 56.13% | 3.93% | 5.99% | 20.85% | 6.55% |
| Normalized Basic EPS | 0.57% | 84.04% | 22.29% | 32.90% | -43.70% |
| EPS Diluted | 56.70% | 3.41% | 5.98% | 20.69% | 5.88% |
| Normalized Diluted EPS | 0.57% | 83.92% | 22.28% | 32.90% | -43.78% |
| Average Basic Shares Outstanding | 0.06% | 0.06% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.06% | 0.13% | 0.00% | 0.00% | 0.13% |
| Dividend Per Share | 6.60% | -- | 7.53% | -- | 0.00% |
| Payout Ratio | -- | 0.07% | -0.27% | -0.18% | -- |
